ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

Phase 2

Completed

Conditions: Noncontiguous Stage II Small Lymphocytic Lymphoma
Stage I Grade 2 Follicular Lymphoma
Stage I Grade 3 Follicular Lymphoma
Stage IV Marginal Zone Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Noncontiguous Stage II Grade 2 Follicular Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Stage I Marginal Zone Lymphoma

Interventions: Biological: pegfilgrastim
Biological: rituximab
Other: flow cytometry
Procedure: biopsy
Other: immunohistochemistry staining method
Genetic: western blotting

First Posted Date: 2012-09-10

Last Posted Date: 2017-10-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT01682044

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy

Phase 2

Terminated

Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx
Chemotherapeutic Agent Toxicity
Stage III Squamous Cell Carcinoma of the Nasopharynx
Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Mucositis
Radiation Toxicity
Stage III Squamous Cell Carcinoma of the Larynx
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity

Interventions: Dietary Supplement: selenomethionine
Other: placebo
Drug: cisplatin
Radiation: radiation therapy
Procedure: quality-of-life assessment

First Posted Date: 2012-09-10

Last Posted Date: 2014-08-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01682031

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇳🇿
Waikato Hospital, Hamilton, New Zealand

Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy

Phase 2

Withdrawn

Conditions: Mucositis
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Recurrent Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Nasopharynx
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Recurrent Verrucous Carcinoma of the Larynx
Recurrent Verrucous Carcinoma of the Oral Cavity
Stage III Squamous Cell Carcinoma of the Hypopharynx

Interventions: Procedure: quality-of-life assessment
Other: placebo
Other: questionnaire administration
Drug: Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules

First Posted Date: 2012-08-28

Last Posted Date: 2013-05-15

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01674374

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Phase 1

Completed

Conditions: Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer

Interventions: Drug: decitabine
Biological: NY-ESO-1 peptide vaccine
Drug: pegylated liposomal doxorubicin hydrochloride
Biological: sargramostim
Biological: incomplete Freund's adjuvant
Other: immunohistochemistry staining method
Other: liquid chromatography
Other: mass spectrometry
Genetic: reverse transcriptase-polymerase chain reaction
Other: laboratory biomarker analysis
Genetic: DNA methylation analysis
Other: enzyme-linked immunosorbent assay

First Posted Date: 2012-08-27

Last Posted Date: 2022-08-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01673217

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy in Treating Patients With Lung Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Lung
Stage 0 Non-small Cell Lung Cancer
Large Cell Lung Cancer
Squamous Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer

Interventions: Drug: HPPH
Drug: photodynamic therapy
Procedure: therapeutic bronchoscopy

First Posted Date: 2012-08-20

Last Posted Date: 2014-07-31

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 17

Registration Number: NCT01668823

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Not Applicable

Terminated

Conditions: Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia
Stage II Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia
Stage 0 Chronic Lymphocytic Leukemia

Interventions: Drug: lenalidomide
Other: laboratory biomarker analysis
Procedure: lymph node biopsy
Procedure: bone marrow aspiration
Other: pharmacological study
Other: flow cytometry

First Posted Date: 2012-07-25

Last Posted Date: 2016-06-30

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 8

Registration Number: NCT01649791

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Bathing Bundle Regimen in Reducing Gynecological Surgical Site Infection in Patients Undergoing Surgery

Not Applicable

Completed

Conditions: Malignant Female Reproductive System Neoplasm

Interventions: Procedure: Infection Prophylaxis and Management

First Posted Date: 2012-05-14

Last Posted Date: 2020-07-23

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 435

Registration Number: NCT01597804

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Phase 1

Terminated

Conditions: Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Cancer
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Drug: panobinostat
Drug: everolimus
Other: laboratory biomarker analysis
Other: pharmacological study
Other: liquid chromatography
Other: mass spectrometry
Other: enzyme-linked immunosorbent assay
Other: immunohistochemistry staining method

First Posted Date: 2012-04-20

Last Posted Date: 2022-08-15

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 26

Registration Number: NCT01582009

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: Smac mimetic TL32711
Drug: gemcitabine hydrochloride
Other: laboratory biomarker analysis
Other: pharmacological study
Procedure: biopsy

First Posted Date: 2012-04-10

Last Posted Date: 2022-08-15

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 21

Registration Number: NCT01573780

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Phase 2

Terminated

Conditions: Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Blastic Phase Chronic Myelogenous Leukemia
Contiguous Stage II Adult Burkitt Lymphoma
de Novo Myelodysplastic Syndromes
Recurrent Adult Burkitt Lymphoma
Untreated Adult Acute Lymphoblastic Leukemia
Untreated Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Previously Treated Myelodysplastic Syndromes
Stage III Adult Burkitt Lymphoma

Interventions: Drug: rasburicase
Drug: allopurinol

First Posted Date: 2012-03-27

Last Posted Date: 2018-01-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 24

Registration Number: NCT01564277

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy